Cumberland Pharmaceuticals INC 8-K filings

Cumberland Pharmaceuticals announced the closing of its strategic transaction with Apotex Health for $100 million, alongside a special dividend and updated clinical trial results.

Cumberland Pharmaceuticals Inc. announced a special cash dividend of $1.50 per share following a strategic transaction with Apotex, alongside a new $5 million share repurchase program.

Cumberland Pharmaceuticals Inc. announced the closing of its strategic transaction with an affiliate of Apotex Inc., selling its branded U.S. product lines for $100 million to focus on rare disease pipeline development.

Cumberland Pharmaceuticals shareholders have voted to approve the strategic asset sale of its commercial products to an affiliate of Apotex Inc.

Cumberland Pharmaceuticals reports Q1 2026 financial results and a $100 million strategic divestiture of its branded portfolio.

Cumberland Pharmaceuticals shareholders approved the election of directors and ratified the appointment of its independent auditor at the 2026 annual meeting.

Cumberland Pharmaceuticals Inc. has entered into a strategic transaction to sell its U.S. branded pharmaceutical business to an affiliate of Apotex Inc. for $100 million.

Cumberland Pharmaceuticals announced robust financial performance in Q4 and full-year 2025, driven by significant revenue growth, international expansion, and key product milestones.

Cumberland Pharmaceuticals announced FDA Fast Track Designation for its novel oral therapy, ifetroban, targeting fatal heart disease in Duchenne muscular dystrophy patients.

Cumberland Pharmaceuticals Inc. amended its revolving credit facility with Pinnacle Bank, extending the maturity date to October 2027 and adjusting borrowing terms.

Cumberland Pharmaceuticals announced a 12% year-to-date revenue increase, the addition of FDA-approved Talicia to its portfolio, and positive clinical trial progress for ifetroban.

Cumberland Pharmaceuticals announced a strategic co-commercialization agreement with RedHill Biopharma for Talicia, an FDA-approved H. pylori treatment, forming a new jointly owned company.

Cumberland Pharmaceuticals reported a 23% increase in year-to-date revenues for the first half of 2025, reaching $22.6 million, alongside significant progress in its clinical development programs.

Cumberland Pharmaceuticals announces a 38% increase in revenue for Q1 2025, reaching $11.7 million, alongside a net profit of $1.3 million.

Cumberland Pharmaceuticals held its annual shareholder meeting on April 22, 2025, and shareholders approved the election of three Class III Directors and the ratification of the company's independent auditor.

Cumberland Pharmaceuticals' Phase 2 FIGHT DMD trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this disease.

Cumberland Pharmaceuticals announced an 11.6% increase in fourth-quarter 2024 revenue, driven by its portfolio of FDA-approved brands, and highlighted positive developments including Phase 2 study results for Duchenne muscular dystrophy and approval of Vibativ in China.

Cumberland Pharmaceuticals and SciClone Pharmaceuticals announce NMPA approval for Vibativ (telavancin) injection in China, paving the way for its launch in the world's second-largest market.

Cumberland Pharmaceuticals has increased the maximum aggregate offering price of its common stock to $10 million under its sales agreement with H.C. Wainwright & Co., LLC.

Cumberland Pharmaceuticals reports successful top-line results from its Phase 2 FIGHT DMD trial, showing improvement in cardiac function with ifetroban treatment for Duchenne muscular dystrophy (DMD) heart disease.

Cumberland Pharmaceuticals received FDA approval for a simplified dosing regimen of its intravenous acetaminophen overdose treatment, Acetadote, designed to improve administration efficiency and patient outcomes.

Cumberland Pharmaceuticals has been granted Orphan Drug and Rare Pediatric Disease Designations by the FDA for Ifetroban, a potential treatment for cardiomyopathy associated with Duchenne muscular dystrophy.

Cumberland Pharmaceuticals announced third-quarter 2024 financial results with $9.1 million in revenue, alongside positive clinical trial updates and new product designations.

A new study demonstrates that Cumberland Pharmaceuticals' Caldolor injection is associated with fewer adverse drug reactions and improved healthcare utilization compared to ketorolac.

Cumberland Pharmaceuticals' Caldolor was not included in the list of products eligible for separate Medicare reimbursement under the NOPAIN Act, despite the company's belief that it meets the criteria.

Cumberland Pharmaceuticals announced a 16% sequential increase in net revenue for the second quarter of 2024, along with improved adjusted earnings.

Cumberland Pharmaceuticals announced first quarter 2024 revenues of $8.5 million, alongside a net loss of $1.9 million, while highlighting progress in clinical development and product launches.

Cumberland Pharmaceuticals' shareholders elected two Class II directors and ratified the appointment of Carr, Riggs & Ingram, LLC as the independent auditor for 2024 at their annual meeting on April 23, 2024.

Cumberland Pharmaceuticals has initiated an at-the-market offering program to sell up to $5.8 million of its common stock.

Cumberland Pharmaceuticals announced its 2023 financial results, reporting $40 million in revenue and $6 million in cash from operations, while also highlighting the expansion of its Caldolor product's FDA approval to include infants.